Introduction of papillomavirus rapid interface for modelling and economics (PRIME) and an example of China′s data analysis
10.3760/cma.j.issn.0253-9624.2019.07.016
- VernacularTitle: 人乳头瘤病毒疫苗建模与经济学评估快速界面模型介绍及中国实例分析
- Author:
Zhaofeng BI
1
;
Yafei LI
;
Feixue WEI
;
Yingying SU
;
Jun ZHANG
Author Information
1. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361102, China
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Vaccines;
Human papillomavirus;
Economics;
PRIME
- From:
Chinese Journal of Preventive Medicine
2019;53(7):744-751
- CountryChina
- Language:Chinese
-
Abstract:
Cervical cancer has become an important disease that jeopardizes women′s health, causing hundreds of thousands of new cases annually. Human papillomavirus (HPV) is the leading cause for cervical cancer. Since the world′s first HPV vaccine was licensed in 2006, 92 countries around the world have introduced them in national immunization programs. The WHO recommends that scientific economic evaluation should be achieved before the introduction, but this is more difficult for low-and middle-income countries. Therefore, this article introduces a mathematical model recommended by WHO in 2014 to quickly and easily accomplish economic evaluation of HPV vaccine -the PRIME, and take the China′s 2018 data published by International Agency for Research on Cancer (IARC) as an example. The evaluation result shows that the introduction of HPV vaccine in Chinese 12-year-old women is cost-effective.
